Comparison of the European and Japanese guidelines for the management of ischemic stroke

Cerebrovascular Diseases

Volumn 35, Issue 5, 2013, Pages 402-418

  Kern, Rolf ^a   Nagayama, Masao ^b   Toyoda, Kazunori ^c   Steiner, Thorsten ^a,d   Hennerici, Michael G ^a   Shinohara, Yukito ^e  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

^c NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^d UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^e Federation of National Public Service Personnel Mutual Aid Associations   (Japan)

Author keywords

Acute stroke treatment; European stroke guidelines; Evidence based medicine; Ischemia; Japanese stroke guidelines; Randomized clinical trials; Review; Stroke prevention

Indexed keywords

ALTEPLASE; ANTIDEPRESSANT AGENT; ANTITHROMBOCYTIC AGENT; ARGATROBAN; NORPHENAZONE;

ALCOHOL CONSUMPTION; ANTICOAGULANT THERAPY; ATRIAL FIBRILLATION; BRAIN CIRCULATION; BRAIN EDEMA; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOEMBOLIC STROKE; CAROTID ENDARTERECTOMY; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; COMPARATIVE STUDY; DECOMPRESSION SURGERY; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DISEASE CLASSIFICATION; DYSLIPIDEMIA; EUROPEAN; FIBRINOLYTIC THERAPY; GROUPS BY AGE; HEALTH EDUCATION; HEMODILUTION; HUMAN; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; JAPANESE (PEOPLE); LUNG EMBOLISM; MEDICAL SOCIETY; METABOLIC SYNDROME X; OBESITY; PATIENT TRANSPORT; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SECONDARY PREVENTION; SLEEP DISORDERED BREATHING; SMOKING; STROKE UNIT;

EID: 84878098149     PISSN: 10159770     EISSN: 14219786     Source Type: Journal    
DOI: 10.1159/000351753     Document Type: Review

References (46)

1. Shinohara Y, Yanagihara T, Abe K, Yoshimine T, Fujinaka T, Chuma T, Ochi F, Nagayama M, Ogawa A, Suzuki N, Katayama Y, Kimura A, Kobayashi S: I. Stroke in general. J Stroke Cerebrovasc Dis 2011; 20(suppl 1):S7-S30.
2. Shinohara Y, Yanagihara T, Abe K, Yoshimine T, Fujinaka T, Chuma T, Ochi F, Nagayama M, Ogawa A, Suzuki N, Katayama Y, Kimura A, Kobayashi S: II. Cerebral infarction/transient ischemic attack (TIA). J Stroke Cerebrovasc Dis 2011; 20(suppl 1):S31-S73.
3. Shinohara Y, Yanagihara T, Abe K, Yoshimine T, Fujinaka T, Chuma T, Ochi F, Nagayama M, Ogawa A, Suzuki N, Katayama Y, Kimura A, Kobayashi S: III. Intracerebral hemorrhage. J Stroke Cerebrovasc Dis 2011; 20(suppl 1):S74-S99.
4. Shinohara Y, Yanagihara T, Abe K, Yoshimine T, Fujinaka T, Chuma T, Ochi F, Nagayama M, Ogawa A, Suzuki N, Katayama Y, Kimura A, Kobayashi S: IV. Subarachnoid hemorrhage. J Stroke Cerebrovasc Dis 2011; 20(suppl 1):S100-S115.
5. Shinohara Y, Yanagihara T, Abe K, Yoshimine T, Fujinaka T, Chuma T, Ochi F, Nagayama M, Ogawa A, Suzuki N, Katayama Y, Kimura A, Kobayashi S: V. Asymptomatic cerebrovascular diseases. J Stroke Cerebrovasc Dis 2011; 20(suppl 1):S116-S128.
6. Shinohara Y, Yanagihara T, Abe K, Yoshimine T, Fujinaka T, Chuma T, Ochi F, Nagayama M, Ogawa A, Suzuki N, Katayama Y, Kimura A, Kobayashi S: VI. Other types of cerebrovascular disorders. J Stroke Cerebrovasc Dis 2011; 20(suppl 1):S129-S144.
7. Shinohara Y, Yanagihara T, Abe K, Yoshimine T, Fujinaka T, Chuma T, Ochi F, Nagayama M, Ogawa A, Suzuki N, Katayama Y, Kimura A, Kobayashi S: VII. Rehabilitation. J Stroke Cerebrovasc Dis 2011; 20(suppl 1):S145-S180.
8. European Stroke Organisation (ESO) Executive Committee, ESO Writing Committee: Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 2008; 25: 457-507.
9. ESO News: Update Guidelines January 2009. Specific Treatment: Thrombolysis. Cerebrovasc Dis 2009; 27: 619-620.
10. Neuroresuscitation; in JRC Guidelines 2010 (in Japanese). Tokyo, Japan Resuscitation Council, 2010. http://jrc.umin.ac.jp/pdf/20121022-NR-E.pdf.
11. Wojner-Alexander AW, Garami Z, Chernyshev OY, Alexandrov AV: Heads down: flat positioning improves blood flow velocity in acute ischemic stroke. Neurology 2005; 64: 1354-1357.
12. Sandset EC, Bath PM, Boysen G, Jatuzis D, Kõrv J, Lüders S, Murray GD, Richter PS, Roine RO, Terént A, Thijs V, Berge E, SCAST Study Group: The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, doubleblind trial. Lancet 2011; 377: 741-750.
13. Minematsu K, Toyoda K, Hirano T, Kimura K, Kondo R, Mori E, Nakagawara J, Sakai N, Shiokawa Y, Tanahashi N, Yasaka M, Katayama Y, Miyamoto S, Ogawa A, Sasaki M, Suga S, Yamaguchi T: Guidelines for intravenous application of rt-PA (alteplase), the second edition, October 2012: a guideline from the Japan Stroke Society. J Stroke Cerebrovasc Dis 2013, in press.
14. Yamaguchi T, Mori E, Minematsu K, Nakagawara J, Hashi K, Saito I, Shinohara Y, Japan Alteplase Clinical Trial (J-ACT) Group: Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT). Stroke 2006; 37: 1810-1815.
15. Mori E, Minematsu K, Nakagawara J, Yamaguchi T, Sasaki M, Hirano T, Japan Alteplase Clinical Trial II Group: Effects of 0.6 mg/kg intravenous alteplase on vascular and clinical outcomes in middle cerebral artery occlusion: Japan Alteplase Clinical Trial II (J-ACT II). Stroke 2010; 41: 461-465.
16. Jauch EC, Saver JL, Adams HP Jr, Bruno A, Connors JJ, Demaerschalk BM, Khatri P, Mc-Mullan PW Jr, Qureshi AI, Rosenfield K, Scott PA, Summers DR, Wang DZ, Wintermark M, Yonas H, American Heart Association Stroke Council, Council on Cardiovascular Nursing, Council on Peripheral Vascular Disease, Council on Clinical Cardiology: Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013; 44: 870-947.
17. Ogawa A, Mori E, Minematsu K, Taki W, Takahashi A, Nemoto S, Miyamoto S, Sasaki M, Inoue T, MELT Japan Study Group: Randomized trial of intraarterial infusion of urokinase within 6 hours of middle cerebral artery stroke: the middle cerebral artery embolism local fibrinolytic intervention trial (MELT) Japan. Stroke 2007; 38: 2633-2639.
18. Tazaki Y, Kobayashi S, Tohgi H, et al: Clinical benefit of an antithrombin agent, MD-805, in acute-phase cerebral thrombosis-a placebocontrolled, multicenter, double-blind, intergroup trial (in Japanese)]. J Clin Exp Med 1992; 161: 887-907.
19. Kobayashi S, Tazaki Y: Effect of the thrombin inhibitor argatroban in acute cerebral thrombosis. Semin Thromb Hemost 1997; 23: 531-534.
20. Fukuuchi Y, Tohgi H, Shinohara Y, et al: A controlled clinical trial to assess the efficacy and safety of argatroban in treating acute cerebral thrombosis in comparison to sodium ozagrel (in Japanese). Neurol Ther 2001; 18: 273-282.
21. Otomo E, Kutuzawa T, Kogure K: Clinical benefit of OKY-046 in acute cerebral thrombosis-a placebo-controlled, multicenter, double-blind trial (in Japanese). J Clin Ther Med 1991; 7: 353-388.
22. Edaravone Acute Infarction Group: Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double blind study at multicenters. Cerebrovasc Dis 2003; 15: 222-229.
23. Ringelstein EB, Chamorro A, Kaste M, Langhorne P, Leys D, Lyrer P, Thijs V, Thomassen L, Toni D, ESO Stroke Unit Certification Committee: European Stroke Organisation recommendations to establish a stroke unit and stroke center. Stroke 2013; 44: 828-840.
24. Ogihara T, Kikuchi K, Matsuoka H, Fujita T, Higaki J, Horiuchi M, Imai Y, Imaizumi T, Ito S, Iwao H, Kario K, Kawano Y, Kim-Mitsuyama S, Kimura G, Matsubara H, Matsuura H, Naruse M, Saito I, Shimada K, Shimamoto K, Suzuki H, Takishita S, Tanahashi N, Tsuchihashi T, Uchiyama M, Ueda S, Ueshima H, Umemura S, Ishimitsu T, Rakugi H, Japanese Society of Hypertension Committee: The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res 2009; 32: 3-107, erratum p 318.
25. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Struijker Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Kjeldsen SE, Erdine S, Narkiewicz K, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Cifkova R, Dominiczak A, Fagard R, Heagerty AM, Laurent S, Lindholm LH, Mancia G, Manolis A, Nilsson PM, Redon J, Schmieder RE, Struijker-Boudier HA, Viigimaa M, Filippatos G, Adamopoulos S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine S, Farsang C, Gaita D, Kiowski W, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O'Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, van Zwieten P, Viigimaa M, Waeber B, Williams B, Zamorano JL, Task Force for the Management of Arterial Hypertension of the European Society of Hypertension, Task Force for the Management of Arterial Hypertension of the European Society of Cardiology: 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28: 1462-536.
26. Cholesterol Treatment Trialists' (CTT) Collaborators, Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C: Efficacy of cholesterol-lowering therapy in 18, 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008; 371: 117-125.
27. Sato H, Ishikawa K, Kitabatake A, et al: Lowdose aspirin for prevention of stroke in lowrisk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial. Stroke 2006; 37: 447-451.
28. Yamaguchi T, Japanese Nonvalvular Atrial Fibrillation-Embolism Secondary Prevention Cooperative Study Group: Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation: a multicenter, prospective, randomized trial. Stroke 2000; 31: 817-821.
29. Yasaka M, Minematsu K, Yamaguchi T: Optimal intensity of international normalized ratio in warfarin therapy for secondary prevention of stroke in patients with non-valvular atrial fibrillation. Intern Med 2001; 40: 1183-1188.
30. Stroke Prevention in Atrial Fibrillation Investigators: Adjusted-dose warfarin versus lowintensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996; 348: 633-638.
31. Hylek EM, Singer DE: Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994; 120: 897-902.
32. Hobson R 2nd, Krupski W, Weiss D: Influence of aspirin in the management of asymptomatic carotid artery stenosis. VA Cooperative Study Group on Asymptomatic Carotid Stenosis. J Vasc Surg 1993; 17: 257-263.
33. Engelter S, Lyrer P: Antiplatelet therapy for preventing stroke and other vascular events after carotid endarterectomy (review). Cochrane Database Syst Rev 2003; 3:CD001458.
34. Mayo Asymptomatic Carotid Endarterectomy Study Group: Results of a randomized controlled trial of carotid endarterectomy for asymptomatic carotid stenosis. Mayo Asymptomatic Carotid Endarterectomy Study Group. Mayo Clin Proc 1992; 67: 513-518.
35. Tanaka K, Ishikawa Y, Yokoyama M, Origasa H, Matsuzaki M, Saito Y, et al: Reduction in the recurrence of stroke by eicosapentaenoic acid for hypercholesterolemic patients: subanalysis of the JELIS trial. Stroke 2008; 39: 2052-2058.
36. Reynolds K, Lewis B, Nolen JD, Kinney GL, Sathya B, He J: Alcohol consumption and risk of stroke: a meta-analysis. JAMA 2003; 289: 579-588.
37. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A: European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143: 1-13.
38. Halkes P, van Gijn J, Kappelle L, Koudstaal P, Algra A: Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006; 367: 1665-1673.
39. CAPRIE Steering Committee: A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-1339.
40. Costa J, Ferro JM, Matias-Guiu J, Alvarez-Sabin J, Torres F: Triflusal for preventing serious vascular events in people at high risk. Cochrane Database Syst Rev 2005; 3:CD004296.
41. Diener H, Bogousslavsky J, Brass L, Cimminiello C, Csiba L, Kaste M, Leys D, Matias-Guiu J, Rupprecht H: Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004; 364: 331-337.
42. Gotoh F, Tohgi H, Hirai S, Terashi A, Fukuuchi Y, Otomo E, et al: Cilostazol stroke prevention study: a placebo-controlled doubleblind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis 2000; 9: 147-157.
43. Huang Y, Cheng Y, Wu J, Li Y, Xu E, Hong Z, et al: Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study. Lancet Neurol 2008; 7: 494-499.
44. Shinohara Y, Katayama Y, Uchiyama S, Yamaguchi T, Handa S, Matsuoka K, Ohashi Y, Tanahashi N, Yamamoto H, Genka C, Kitagawa Y, Kusuoka H, Nishimaru K, Tsushima M, Koretsune Y, Sawada T, Hamada C, CSPS 2 Group: Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised noninferiority trial. Lancet Neurol 2010; 9: 959-968.
45. Japanese Circulation Society. Circ J 2004; 68(suppl IV):1195-1196.
46. Powers WJ, Clarke WR, Grubb RL Jr, Videen TO, Adams HP Jr, Derdeyn CP, COSS Investigators: Extracranial-intracranial bypass surgery for stroke prevention in hemodynamic cerebral ischemia: the Carotid Occlusion Surgery Study randomized trial. JAMA 2011; 306: 1983-1992.